Tonkin A M, Joel S E, Reynolds J L, Aylward P E, Heddle W F, McRitchie R J, West M J, Chalmers J P
Med J Aust. 1981 Aug 8;2(3):145-6. doi: 10.5694/j.1326-5377.1981.tb100839.x.
The effects of orally administered timolol maleate (10 mg twice a day) were assessed in 88 patients entered into a double-blind study within 10.74 +/- 5.07 hours of onset of myocardial infarction. Timolol maleate produced no significant change in crude mortality rate, infarct size, incidence of arrhythmias or significant left ventricular failure. Withdrawals from study because of recurrent angina or hypertension were confined to the placebo group. The results of this study suggested that, when given relatively late after infarction, timolol maleate does not reduce either infarct size or incidence of arrhythmias, despite production of a safe and effective beta-blockade.
对88例在心肌梗死发病10.74±5.07小时内进入双盲研究的患者,评估了口服马来酸噻吗洛尔(每日两次,每次10毫克)的效果。马来酸噻吗洛尔在粗死亡率、梗死面积、心律失常发生率或严重左心室衰竭方面未产生显著变化。因复发性心绞痛或高血压而退出研究的情况仅限于安慰剂组。本研究结果表明,在梗死相对较晚时给予马来酸噻吗洛尔,尽管能产生安全有效的β受体阻滞作用,但并不能缩小梗死面积或降低心律失常的发生率。